Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 9, 2004

View Archived Issues

In vitro effects of the novel immunomodulator MDP-C

Xencor and Genentech collaborate on next-generation therapeutic antibodies

Isis reports on alicaforsen trial results

ISA-247 investigated for psoriasis in Canadian phase III study

Shark tissue extract shown to have antitumor activity in vitro

Identification of two Candida albicans formins

Beneficial effects of curcumin may be mediated in part by iron chelation

Selective, orally active VEGF receptor inhibitor effective against human lung cancer in murine model

Novel tetrahydroisoquinoline derivatives show insulin-sensitizing effects with fewer side effects

AnorMED receives FDA response to SPA for AMD-3100 phase III program

CYT005-AllQbG10 enters phase II house dust mite allergy trial

Target enrollment reached in phase III study of methylnaltrexone

FDA requests phase III trials prior to Metvix approval in basal cell carcinoma

Genta acquires rights to c-myb antisense drug

SGN-40 enters new phase I trial in NHL

Single-use vial of Vitrase approved for use as spreading agent

Oxazolidinone antibacterial agents covered by Ranbaxy patent

Suntory describes novel agents for the treatment of thrombosis

Pfizer claims NR2B receptor antagonists for pain, stroke, etc.

Novel dosage formulations of proton pump antagonists presented by Altana Pharma

Semafore describes PI-3 kinase inhibitor prodrugs in patent literature

Two series of calcium channel blockers patented by NeuroMed

Phase II data on the effects and safety of aselizumab in patients with multiple trauma

DHEA shows promise in the management of abdominal obesity

Update on the survival effects of BLP-25 in NSCLC

New data on the toxicity and pharmacokinetics of XR-11576 in advanced cancer patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...